GUTS · Fractyl Health, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As a result, we have concluded that substantial doubt exists about our ability to continue as a going concern for at least one year after the date that these financial statements are issued.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Fractal's Remain One pivotal study met its six-month co-primary endpoint with a p-value of 0.0023, with Revita participants keeping about 80% of the weight they had lost on trisepatide. Fractal cut its workforce by approximately 45%, and it expects quarterly operating cash spending to fall to approximately $8 million by the end of the second quarter of 2027. Twelve-month data are due in the first quarter of 2027.
Fractal Health met Remain One’s six-month co-primary endpoint (p-value 0.0023) and plans Revita’s de novo submission for late 2026. A 45% workforce reduction targets approximately $8 million quarterly cash spending and runway into the second quarter of 2027.
Fractyl Health, Inc. said Revita met its six-month weight-retention endpoint (p=0.0023) and will reduce headcount by approximately 45%, while $31.5 million in cash funds operations only into the second quarter of 2027 and creates substantial going-concern doubt.
Fractyl Health, Inc. said Revita met its endpoint, with approximately 80% weight-loss retention versus 67% for sham. A late Q4 2026 FDA De Novo submission is planned; cash runs into Q2 2027 amid a workforce cut of approximately 45%.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 15, 2026TL;DR. Fractyl reported one-year randomized REMAIN-1 Midpoint and open-label REVEAL-1 data supporting durable post-GLP-1 weight maintenance with Revita, with pivotal REMAIN-1 6-month topline data on track for early Q4 2026 and a potential De Novo submission targeted for late Q4 2026. The company ended Q2 with $47.1 million in cash, guiding runway only into early 2027 and stating no plan to raise capital before pivotal data.
- + One-year randomized REMAIN-1 Midpoint data showed Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in the optimized complete-ablation population.
- + Q2 2026 R&D expenses fell to $13.8 million from $21.2 million year over year, driving a $7.7 million improvement in Adjusted EBITDA loss to negative $16.3 million.
- + Revita had zero device- or procedure-related serious adverse events through one year across both reported cohorts, supporting a favorable safety profile.
- + Management stated the company is funded through definitive pivotal data and does not plan to raise capital before the readout, with $47.1 million in cash extending runway into early 2027.
- − Q2 2026 net loss was $25.5 million, with a $5.1 million higher non-cash loss from change in fair value of warrant liabilities worsening the bottom line versus the prior year.
- − Management declined to provide Revita launch volume, pricing, or unit economics assumptions ahead of the September Investor Day, leaving commercial profitability and reimbursement specifics uncertain.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$50.34M | Nine Months Ended September 30, 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GUTS
this stock
Fractyl Health, Inc.
|
$12.67M | — | -100.0% | — | 4.4% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GUTS | +17.6% | -15.5% | -90.8% | -2.2% | -96.4% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +23.1% | -9.2% | -85.2% | +3.1% | -101.4% |